Sign In
Buy SILO
$4.19
-0.0600 (-1.41%)
At Close: Jul 31, 2026
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
08:32am, Tuesday, 05'th Aug 2025
Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), today announced the launch of
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
08:45am, Wednesday, 16'th Jul 2025
SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and dr
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
08:15am, Monday, 07'th Jul 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”),
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
08:27am, Wednesday, 25'th Jun 2025
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance G
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
09:00am, Wednesday, 11'th Jun 2025
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and dr
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
09:15am, Thursday, 05'th Jun 2025
Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value Strategic decision positions Company to diversify treasury holdings with a long-term digital
Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo," or the "Company") is pleased to announce a proposed name change to "Born Defense" and a c
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
08:55am, Wednesday, 21'st May 2025
Study is expected to deliver final device data and documentation needed for planned FDA IND submission Study is expected to deliver final device data and documentation needed for planned FDA IND submi
Silo Pharma Announces Closing of $2 Million Public Offering
04:15pm, Friday, 16'th May 2025
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and dru
Silo Pharma Announces Pricing of $2 Million Public Offering
09:15am, Thursday, 15'th May 2025
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and dru
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
04:07pm, Wednesday, 14'th May 2025
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and dru
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
08:40am, Wednesday, 14'th May 2025
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
08:11am, Wednesday, 30'th Apr 2025
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
07:50am, Monday, 28'th Apr 2025
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and d
